[
    {
        "pregunta": "1. Why can pregnancy-induced hypertension syndromes be confused with active RMD flares?",
        "respuesta": "Los síndromes hipertensivos inducidos por el embarazo, como la preeclampsia, pueden confundirse con brotes activos de enfermedades reumáticas inflamatorias (RMD) porque ambos presentan manifestaciones clínicas y de laboratorio similares. Por ejemplo:\n\n- La preeclampsia puede producir hipertensión arterial, proteinuria y disfunción renal, que pueden asemejarse a nefritis lúpica activa, crisis renal en esclerodermia o vasculitis activa.  \n- El síndrome HELLP (hemólisis, elevación de enzimas hepáticas y plaquetas bajas) o la eclampsia pueden parecer brotes graves de enfermedad, dado que también presentan manifestaciones multisistémicas graves.  \n- Además, algunos síntomas normales del embarazo como eritrosedimentación elevada, anemia y artralgias difusas pueden mimetizar signos de actividad inflamatoria.\n\nEsta superposición clínica y analítica dificulta la diferenciación entre síndromes hipertensivos del embarazo y brotes de RMD, requiriendo la evaluación conjunta y especializada de reumatólogos y especialistas en obstetricia-medicina maternofetal para un diagnóstico y manejo adecuados.",
        "contexto": [
            "In addition, normal pregnancy symptoms such as malar erythema, chloasma gravidarum, anemia, elevated erythrocyte sedimentation, and diffuse arthralgias may falsely mimic symptoms of active RMD. Pregnancy-induced hypertension syndromes (preeclampsia) may be confused with lupus nephritis, scleroderma renal crisis, or vasculitis flare. HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) or eclampsia may resemble severe disease flare. Distinguishing among these syndromes requires",
            "severe disease flare. Distinguishing among these syndromes requires the expertise of rheumatologists and obstetrics-gynecology or maternal-fetal medicine physicians working together. Most information regarding pregnancy management in RMD comes from observational studies, primarily in patients with SLE and APS. There have been very few controlled trials. Data about pregnancies in rare rheumatic diseases usually derive from small case series. For these reasons, many recommendations are",
            "including those with SLE Pregnancy: general assessment, counseling, and management Obstetrics-gynecology or maternal-fetal medicine specialists necessarily assume primary medical management of pregnancy in a woman with RMD. An understanding of basic pregnancy physiology is helpful for rheumatologists to identify and treat active disease during pregnancy and coordinate care with obstetric providers. Pregnancy changes may impact manifestations of RMD. Pregnancy-related increased intravascular",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular",
            "arterial hypertension, renal dysfunction, heart failure, or other severe organ damage, pregnancy may be contraindicated due to high risk of maternal morbidity and mortality. In women with RMD planning pregnancy who are receiving medication that is incompatible with pregnancy, we strongly recommend switching to a pregnancycompatible medication and observing for sufficient time to assess efficacy and tolerability of the new medication. There are no data to support a specific period of time for"
        ]
    },
    {
        "pregunta": "2. What is the rationale behind conditionally recommending continuation of methotrexate (MTX) in men planning to father a pregnancy?",
        "respuesta": "La justificación para recomendar **condicionalmente** la continuación del metotrexato (MTX) en hombres que planean ser padres se basa en que, aunque la etiqueta del medicamento sugiere la interrupción antes de intentar el embarazo, **los datos disponibles no muestran evidencia de mutagénesis ni teratogenicidad con el uso de MTX en este contexto**. \n\nPor tanto, pese a la recomendación etiquetada tradicionalmente, la evidencia indica que no hay un riesgo comprobado significativo de daño genético o teratogénico relacionado con la exposición paternal a MTX, lo que justifica la continuación condicional del tratamiento en hombres que desean concebir. \n\nNo obstante, esta recomendación es condicional debido a la calidad limitada de la evidencia.",
        "contexto": [
            "attempting conception. Paternal use of CYC may impair spermatogenesis or be mutagenic for DNA In men with RMD who are planning to father a pregnancy, we strongly recommend continuation of HCQ, azathioprine, 6-mercaptopurine, colchicine, and tumor necrosis factor inhibitors In men with RMD who are planning to father a pregnancy, we conditionally recommend, based on a smaller body of evidence, continuing treatment with MTX, MMF, leflunomide, sulfasalazine, calcineurin inhibitors, and nonsteroidal",
            "MMF, leflunomide, sulfasalazine, calcineurin inhibitors, and nonsteroidal antiinflammatory drugs (NSAIDs) Although the drug label suggests discontinuation of MTX before attempting pregnancy, data show no evidence for mutagenesis or teratogenicity Although sulfasalazine may affect sperm count and quality, there are no data suggesting teratogenicity We conditionally recommend continuation of anakinra and rituximab based on limited data Maternal medication use. Supplementary Appendix 7, Tables I",
            "|Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients with only partial response to the current therapy or in those who potentially have not had enough time to adequately respond.| |</p>",
            "is no clinical prototype unconditionally warranting treatment with MTX, rather the use of this drug should be discussed on an individual basis. In clinical practice, MTX may be considered for example in female patients The panel also reached a consensus that MTX should be considered in patients who have relapsed (either on or off GCs), cases without significant response to GC or patients experiencing GC-related adverse events. The group further agreed that MTX may be used with oral or i.m. GC",
            "Despite minimal passage of MTX into breast milk, especially with once-weekly dosing, this medication may accumulate in neonatal tissues DISCUSSION Patients' reproductive health concerns are relevant for all practicing rheumatologists. Issues regarding contraception, fertility, pregnancy, lactation, and the offspring's health affect almost every patient across all RMD diagnoses. The importance of this area is highlighted by recent publications that have addressed key elements of reproductive"
        ]
    },
    {
        "pregunta": "3. What are the risks and benefits of using prednisone in pregnant women with APS who fail standard therapy?",
        "respuesta": "Según la información proporcionada, el uso de prednisona en mujeres embarazadas con síndrome antifosfolípido (APS) que no responden al tratamiento estándar (aspirina de baja dosis y heparina profiláctica o tratamiento con heparina de bajo peso molecular) **no está recomendado de forma rutinaria** debido a la falta de evidencia que demuestre beneficios claros y al potencial riesgo de daño materno y fetal asociado con el uso continuo de glucocorticoides en dosis altas.\n\nEspecíficamente:\n\n- **Beneficios:** No hay datos suficientes que demuestren que añadir prednisona a la terapia estándar mejore los resultados del embarazo en APS obstétrico refractario.\n\n- **Riesgos:** El uso de glucocorticoides, especialmente en dosis elevadas o prolongadas, conlleva potencial para daño materno y fetal, por lo que debe evitarse si no hay una indicación clara y justificada.\n\n- En casos individuales de alto riesgo (por ejemplo, triple positividad, resultados altamente positivos de anticoagulante lúpico, edad materna avanzada o embarazo por fertilización in vitro), puede considerarse el uso cuidadoso de glucocorticoides tras una valoración exhaustiva y discusión del riesgo-beneficio entre médico y paciente.\n\nEn resumen, la guía **recomienda fuertemente en contra de agregar prednisona a la terapia estándar para APS obstétrico** debido a la falta de beneficio comprobado y al riesgo de efectos adversos, reservando su uso para situaciones excepcionales con valoración personalizada.",
        "contexto": [
            "aspirin for preeclampsia prophylaxis in SLE and aPL patients is a low-risk intervention, its effectiveness is not known. Management of OB APS is one area with moderately strong evidence, but treatment for women with recurring adverse outcomes despite standard therapy is needed. Much in the field of prevention, screening, and management of NLE requires further study. There are very limited data on RMD medication effects on fertility and teratogenicity in men with RMD. Because women with RMD who",
            "standard therapy with low-dose aspirin and prophylactic heparin or LMWH. Prophylactic-dose heparin and aspirin therapy for OB APS improves likelihood of live birth, but not necessarily full-term birth. Pregnancy loss occurs, despite treatment, in 25% of OB APS pregnancies. There are no data demonstrating improved outcomes with a higher dose of heparin, and only anecdotal data support the use of intravenous immunoglobulin. We strongly recommend against adding prednisone to prophylactic-dose",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's",
            "in individual high-risk circumstances, such as triple-positive aPL or strongly positive LAC results, advanced maternal age, or IVF pregnancy, may outweigh risks of this therapy, and decisions should be made with discussion between physician and patient, weighing potential risks and benefits. Other therapies for refractory OB APS. Despite improved outcomes with standard therapy with low-dose aspirin and prophylactic heparin/LMWH, additional treatments are needed for patients who do not respond",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically"
        ]
    },
    {
        "pregunta": "4. What is the recommended approach to emergency contraception in women with RMD, including those with SLE or positive aPL?",
        "respuesta": "La información proporcionada **no incluye datos específicos ni recomendaciones detalladas sobre el manejo o las opciones de anticoncepción de emergencia en mujeres con enfermedades reumáticas inflamatorias (RMD), incluyendo lupus eritematoso sistémico (LES) o positividad para anticuerpos antifosfolípidos (aPL)**.\n\nPor lo tanto, no es posible ofrecer una respuesta basada en la evidencia disponible sobre el enfoque recomendado para la anticoncepción de emergencia en esta población.\n\nSe sugiere consultar guías especializadas en salud reproductiva y reumatología para un manejo adecuado y actualizado en estos casos.",
        "contexto": [
            "197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's",
            "aspirin for preeclampsia prophylaxis in SLE and aPL patients is a low-risk intervention, its effectiveness is not known. Management of OB APS is one area with moderately strong evidence, but treatment for women with recurring adverse outcomes despite standard therapy is needed. Much in the field of prevention, screening, and management of NLE requires further study. There are very limited data on RMD medication effects on fertility and teratogenicity in men with RMD. Because women with RMD who",
            "assessment, and management in women with rheumatic and musculoskeletal disease (RMD). SLE = systemic lupus erythematosus; HCQ = hydroxychloroquine; NLE = neonatal lupus erythematosus; aPL = antiphospholipid antibody (persistent moderate-to-high-titer anticardiolipin or anti-β 2 -glycoprotein I antibody or persistent positive lupus anticoagulant); APS = antiphospholipid syndrome (obstetric and/or thrombotic); obstetric APS (OB APS) = patients meeting laboratory criteria for APS and having prior",
            "estrogen-containing contraceptives have not been studied in SLE patients with moderate or severe disease activity. Antiphospholipid antibody-positive patients. Presence of aPL, with or without history of clinical complications, is a contraindication to use of estrogen-containing contraceptives due the potential further increase in thrombosis risk. We strongly recommend against combined estrogen-progestin contraceptives in women with positive aPL because estrogen increases risk of"
        ]
    },
    {
        "pregunta": "5. Why is depot medroxyprogesterone acetate (DMPA) generally avoided in patients at risk for osteoporosis with rheumatic diseases?",
        "respuesta": "El uso de acetato de medroxiprogesterona en depósito (DMPA) se **evita generalmente en pacientes con riesgo de osteoporosis y enfermedades reumáticas (RMD)** porque los estudios muestran que su uso puede producir una **disminución de la densidad mineral ósea de hasta un 7.5% durante 2 años** en poblaciones saludables. \n\nAunque no hay datos publicados que indiquen un aumento en el riesgo de fracturas, la American College of Obstetricians and Gynecologists (ACOG) recomienda mantener cautela con el uso de DMPA en mujeres con o en riesgo aumentado de osteoporosis. \n\nPor ello, en mujeres con RMD que ya tienen un riesgo incrementado de osteoporosis debido al uso de glucocorticoides o a la propia enfermedad, el panel **recomienda condicionalmente evitar el uso prolongado de DMPA para la anticoncepción** como medida preventiva frente a la pérdida ósea.",
        "contexto": [
            "studies in women with HIV show no increase In women with RMD who are at increased risk for osteoporosis from glucocorticoid use or underlying disease, we conditionally recommend against using DMPA as a longterm contraceptive because data suggest that bone mineral density declines by up to 7.5% over 2 years of use in a healthy population Although there are no published data suggesting increased fracture risk, the American College of Obstetricians and Gynecologists recommends caution regarding",
            "College of Obstetricians and Gynecologists recommends caution regarding DMPA use in women with or at increased risk for osteoporosis We conditionally recommend that women with RMD taking mycophenolate mofetil/mycophenolic acid (MMF) use an IUD alone or 2 other methods of contraception together, because MMF may reduce serum estrogen and progesterone levels (in turn reducing the efficacy of oral contraceptives). The Mycophenolate Risk Evaluation and Mitigation Strategy program suggests use of an",
            "RMD SLE Low disease activity SLE Mod-high disease activity AVOID combined estrogenprogestin contraceptives LEGEND Avoid DMPA in patients at risk for osteoporosis Detailed definitions of aPL and antiphospholipid syndrome (APS) are presented in Supplementary Appendix 8 (available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley. com/doi/10.1002/art.41191/abstract Patients with lower-titer aCL and/or anti-β 2 GPI (or noncriteria aPL) who do not meet laboratory",
            "| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|\n| |Women receiving MMF: Use IUD or 2 other methods together [11]|Conditional|\n| |RMD without SLE or aPL: Use highly effective or effective methods† [1]|Strong|\n| |Highly effective methods preferred to effective methods [1A]|Conditional|\n|SLE|SLE with negative aPL and low/stable disease activity: Use highly effective or effective methods† [2]|Strong|\n| |Highly effective methods preferred to effective methods [2A]|Conditional|",
            "<ul>\n<li>RMD = rheumatic and musculoskeletal disease; LARC = long-acting reversible contraception; IUD = intrauterine device; DMPA = depot medroxyprogesterone acetate; IM = intramuscular; aPL = antiphospholipid antibody; OP = osteoporosis; SLE = systemic lupus erythematosus; STD = sexually transmitted disease.</li>\n</ul>\n\n<p>† Percent of women who will become pregnant within the first year of typical use.</p>\n\n<p>‡ Methods based on the timing of the menstrual cycle.</p>"
        ]
    },
    {
        "pregunta": "6. What is the rationale for recommending the use of two contraceptive methods together or an IUD alone in women with RMD taking mycophenolate mofetil (MMF)?",
        "respuesta": "La justificación para recomendar el uso combinado de dos métodos anticonceptivos o el uso exclusivo de un dispositivo intrauterino (DIU) en mujeres con enfermedades reumáticas inflamatorias (RMD) que están tomando micofenolato mofetilo (MMF) se basa en que **el MMF puede reducir los niveles séricos de estrógeno y progesterona**, lo que a su vez **disminuye la eficacia de los anticonceptivos orales hormonales**.\n\nPor esta razón, se **recomienda condicionalmente** que estas mujeres utilicen un DIU solo (cobre o progestina) o bien dos métodos anticonceptivos combinados para asegurar una protección anticonceptiva efectiva.\n\nEste consejo forma parte del programa de Evaluación y Mitigación de Riesgos (Risk Evaluation and Mitigation Strategy) para el micofenolato, que reconoce el riesgo de falla anticonceptiva relacionado con la reducción de hormonas por el MMF.",
        "contexto": [
            "College of Obstetricians and Gynecologists recommends caution regarding DMPA use in women with or at increased risk for osteoporosis We conditionally recommend that women with RMD taking mycophenolate mofetil/mycophenolic acid (MMF) use an IUD alone or 2 other methods of contraception together, because MMF may reduce serum estrogen and progesterone levels (in turn reducing the efficacy of oral contraceptives). The Mycophenolate Risk Evaluation and Mitigation Strategy program suggests use of an",
            "that mycophenolate-containing medications may interfere with hormonal contraceptive efficacy. Since IUDs are the most effective contraceptive options, we strongly recommend the IUD (copper or progestin) for women with RMD who are receiving immunosuppressive therapy, despite hypothetical infection risk. IUD-associated infection risk in RMD patients receiving immunosuppressive therapy has not been specifically studied, but studies in women with HIV show no increase In women with RMD who are at",
            "| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|\n| |Women receiving MMF: Use IUD or 2 other methods together [11]|Conditional|\n| |RMD without SLE or aPL: Use highly effective or effective methods† [1]|Strong|\n| |Highly effective methods preferred to effective methods [1A]|Conditional|\n|SLE|SLE with negative aPL and low/stable disease activity: Use highly effective or effective methods† [2]|Strong|\n| |Highly effective methods preferred to effective methods [2A]|Conditional|",
            "<ul>\n<li>RMD = rheumatic and musculoskeletal disease; LARC = long-acting reversible contraception; IUD = intrauterine device; DMPA = depot medroxyprogesterone acetate; IM = intramuscular; aPL = antiphospholipid antibody; OP = osteoporosis; SLE = systemic lupus erythematosus; STD = sexually transmitted disease.</li>\n</ul>\n\n<p>† Percent of women who will become pregnant within the first year of typical use.</p>\n\n<p>‡ Methods based on the timing of the menstrual cycle.</p>",
            "Risk Evaluation and Mitigation Strategy program suggests use of an IUD alone (copper or progestin is not specified), or an estrogen-progestin contraceptive or the progestin implant together with a barrier contraceptive Assisted reproductive technology As is the case with any underlying significant medical disease, women undertaking ovarian stimulation must be cleared medically by the appropriate specialist. Similarly, women with APS, thrombotic or otherwise, should be cleared medically by their"
        ]
    },
    {
        "pregunta": "7. What is the recommended management of rituximab treatment in pregnant patients with severe, life- or organ-threatening rheumatic disease?",
        "respuesta": "En pacientes embarazadas con enfermedades reumáticas graves que amenazan la vida o el órgano, la recomendación es **continuar el tratamiento con rituximab** de forma condicional si la gravedad de la enfermedad lo justifica. \n\nAdemás, se sugiere continuar rituximab mientras la mujer intenta concebir, siempre considerando un balance entre riesgos del medicamento y de la enfermedad activa. Sin embargo, la administración de rituximab en la segunda mitad del embarazo conlleva un alto riesgo de que el feto tenga niveles mínimos de células B, por lo que su uso debe evaluarse cuidadosamente.\n\nEn resumen:  \n- **Continuar rituximab durante el embarazo** en casos de enfermedad materna grave o que amenace órganos, con monitoreo estrecho.  \n- **Discutir riesgos y beneficios antes y durante el embarazo**.  \n- Considerar la interrupción en momentos no críticos o si la enfermedad lo permite.\n\nEsta recomendación está basada en la evidencia y valoración actual disponible para poblaciones con enfermedades reumáticas inflamatorias graves durante el embarazo.",
        "contexto": [
            "pregnancy, the physician and patient should discuss and weigh the possible risks from these medications versus the risks of uncontrolled disease during pregnancy. We conditionally recommend continuing treatment with rituximab while a woman is trying to conceive, and we conditionally recommend continuing rituximab during pregnancy if severe life-or organ-threatening maternal disease so warrants. Dosing in the second half of pregnancy puts the fetus at high risk of having minimal B cells at",
            "| Rituximab                                | + (Discontinue at conception)                                     | + (Life-/organ-threatening disease)                            | ++                                                             |",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |",
            "regarding infant rotavirus vaccination after in utero exposure to either TNFi or rituximab should be discussed with the pregnant RMD patient prior to delivery. Specifically, the pregnant patient should be educated as to the fact that medications that cross the placenta may affect vaccination schedules for their infants. A copy of the current vaccine guideline summary ( https:// www.rheumatology.org/Portals/0/Files/Vaccinations-Guidance- Whether to give multiple vaccinations to patients with RMD",
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose."
        ]
    },
    {
        "pregunta": "8. How does fetal echocardiography monitoring change for women with a prior infant affected by NLE or CHB?",
        "respuesta": "En mujeres embarazadas con anticuerpos anti-Ro/SSA y/o anti-La/SSB que han tenido previamente un hijo afectado por lupus eritematoso neonatal (NLE) o bloqueo cardíaco congénito (CHB), se recomienda **condicionalmente** realizar ecocardiografía fetal **semanalmente desde la semana 16-18 hasta la semana 26** del embarazo.\n\nEsta frecuencia es mayor en comparación con mujeres sin un hijo previo con NLE/CHB, en quienes se sugiere una ecocardiografía fetal seriada pero con intervalos menos frecuentes (intervalo no determinado), igualmente comenzando entre las semanas 16 y 18 y continuando hasta la semana 26.\n\n**Resumen:**  \n- **Mujeres con historia previa de hijo con NLE o CHB:** ecocardiografía fetal semanal entre semanas 16-26 (recomendación condicional).  \n- **Mujeres sin historia previa:** ecocardiografía fetal seriada, con intervalos menos frecuentes y sin intervalo definido, entre semanas 16-26 (recomendación condicional).\n\nEstas recomendaciones buscan detectar precozmente signos de bloqueo cardíaco y permitir intervenciones oportunas, tomando en cuenta la mayor probabilidad de recurrencia en estos casos.",
        "contexto": [
            "infant who had either cutaneous or cardiac NLE http://onlin elibr ary. wiley.com/doi/10.1002/art.41191/ abstract http:// onlin In pregnant women with anti-Ro/SSA and/or anti-La/ SSB antibodies but no history of an infant with CHB or NLE, we conditionally recommend serial fetal echocardiography (less frequent than weekly; interval not determined) starting between 16 and 18 weeks and continuing through week 26. For women with a prior infant with CHB or other NLE we conditionally recommend fetal",
            "with a prior infant with CHB or other NLE we conditionally recommend fetal echocardiography weekly, starting at week 16-18 and continuing through week 26. Recommendations regarding monitoring for and treatment of CHB in women with anti-Ro/SSA and/or anti-La/SSB are all conditional. Given the rarity of CHB, large case series are not available; most studies are retrospective and not randomized. An argument against screening includes the risk of identification and treatment of artifacts that do",
            "|Positive anti-Ro/SSA with or without anti-La/SSB|Treat with HCQ during pregnancy [69, 70]|Conditional|\n|If no prior history of neonatal lupus: Serial (interval uncertain) fetal echocardiography in weeks 16–26 [67]|Conditional| |\n|If prior history of neonatal lupus: Weekly fetal echocardiography in weeks 16–26 [68]|Conditional| |\n|Medication|Paternal medication| |\n|If planning to father a child: Discuss medication use including CYC|GPS| |",
            "by or associated with maternal anti-Ro/SSA (commonly) and anti-La/SSB autoantibodies. While isolated anti-La/SSB rarely imposes risk, when combined with anti-Ro/SSA, La/SSB antibodies may increase fetal risk Complete (third-degree) heart block (CHB) occurs in ~2% of pregnancies of women with anti-Ro/SSA and/or anti-La/SSB antibodies who have not had a prior infant with NLE, and in 13-18% of pregnancies of women with a prior infant who had either cutaneous or cardiac NLE http://onlin elibr ary.",
            "for anti-Ro/SSA and/or anti-La/SSB antibodies with HCQ during pregnancy. This is based on early and limited data and the low risk profile of HCQ. Retrospective studies demonstrate that in pregnant women with a prior child with cardiac NLE who take HCQ, there is a lower risk of the current fetus developing CHB For pregnant women with anti-Ro/SSA and/or anti-La/ SSB antibodies and fetal first-or second-degree heart block shown on echocardiography, we conditionally recommend treatment with oral"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding the use of prophylactic prednisone in patients undergoing assisted reproductive technology with active SLE?",
        "respuesta": "La recomendación es **no usar prednisona profiláctica** de forma empírica en pacientes con lupus eritematoso sistémico (LES) activo que se someten a técnicas de reproducción asistida (TRA). En lugar de ello, se sugiere un monitoreo cuidadoso del paciente y tratar el eventual brote (flare) si este ocurre.  \n\nNo existen estudios que hayan evaluado la prescripción de prednisona profiláctica para prevenir brotes de LES durante las TRA.",
        "contexto": [
            "estrogen levels may worsen active disease. We conditionally recommend against an empiric dosage increase of prednisone during ART procedures in patients with SLE; instead, we suggest monitoring the patient carefully and treating for flare if it occurs. No studies have evaluated prescription of prophylactic prednisone to prevent SLE flare during ART. Antiphospholipid antibody-positive patients. Patients who are positive for aPL are at increased risk for thrombosis. Most reports of aPL-positive",
            "Avoid prophylactic use of prednisone unless required to control active disease SLE patients. Data on IVF cycles in RMD patients are limited; however, the intended outcome of IVF, pregnancy, may be adversely affected by the presence of active RMD. In addition, there is concern that flare in SLE patients might be worsened in the setting of elevated estrogen levels. We strongly recommend deferring ART procedures in patients with any RMD while disease is moderately or severely active; this",
            "| |Oocyte cryopreservation: Continue medications except CYC [28]|Strong|\n| |Active disease: Defer assisted reproductive technology until disease is stable/quiescent [27]|Strong|\n|SLE|Active SLE: Defer assisted reproductive technology until disease is stable/quiescent [27]|Strong|\n| |Do not treat with prophylactic prednisone [29]|Conditional|\n|Positive aPL|No prior thromboses or OB APS: Prophylactic heparin or LMWH [25A]|Conditional|",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's",
            "aspirin 81 mg daily as prophylaxis in all patients at high risk for preeclampsia Because active disease affects maternal and pregnancy outcome, we strongly suggest, as good practice, monitoring SLE disease activity with clinical history, examination, and laboratory tests at least once per trimester. Abnormalities in the complete blood cell count, differential cell count, urinalysis results and urinary protein:creatinine ratio, or anti-DNA, C3, or C4 levels may indicate possible SLE flare and/or"
        ]
    },
    {
        "pregunta": "10. Under what circumstances is stress-dose glucocorticoid administration recommended during delivery in patients with rheumatic diseases?",
        "respuesta": "La administración de glucocorticoides en dosis de estrés durante el parto en pacientes con enfermedades reumáticas inflamatorias **no se recomienda de forma rutinaria en el parto vaginal**.  \n\nSin embargo, se **recomienda condicionalmente la administración de glucocorticoides en dosis de estrés en el momento del parto quirúrgico (cesárea)**.  \n\nEsta recomendación condicional considera que el estrés fisiológico y quirúrgico asociado a una cesárea puede justificar el uso de dosis de estrés para prevenir insuficiencia suprarrenal en pacientes que reciben glucocorticoides crónicos.  \n\nEn resumen:  \n- **Parto vaginal:** no se recomienda rutinariamente glucocorticoides en dosis de estrés.  \n- **Parto por cesárea:** se recomienda condicionalmente glucocorticoides en dosis de estrés.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's"
        ]
    },
    {
        "pregunta": "11. Why might aspirin be withheld prior to oocyte retrieval in patients undergoing ART?",
        "respuesta": "La aspirina podría suspenderse antes de la recuperación ovocitaria en pacientes que se someten a técnicas de reproducción asistida (TRA) debido a la preocupación de que su acción prolongada aumente el riesgo de hemorragia durante el procedimiento de recuperación ovocitaria. Por ello, generalmente no se usa aspirina antes de la recuperación, y se inicia después de esta si está indicada.",
        "contexto": [
            "therapy throughout pregnancy. Aspirin is not commonly used prior to oocyte retrieval (it will be started after retrieval if indicated) given concern that its prolonged action may increase bleeding risk at the time of the retrieval. Patients receiving regular anticoagulation therapy with vitamin K antagonists for thrombotic APS should transition to therapeutic-dose LMWH for ART (usually enoxaparin 1 mg/kg subcutaneously every 12 hours), with this treatment withheld for retrieval and resumed",
            "and resumed following retrieval. Optimal duration of prophylactic LMWH for asymptomatic aPL-positive patients undergoing ovarian stimulation has not been studied; this is a decision best made in consultation with the reproductive endocrinology and infertility specialist. The treatment is often continued until estrogen levels return to near-physiologic levels if no pregnancy occurs. Patients with OB APS will continue therapy throughout pregnancy. Aspirin is not commonly used prior to oocyte",
            "every 12 hours), with this treatment withheld for retrieval and resumed subsequently, to continue throughout pregnancy. Since ovarian stimulation protocols vary, discussion with the reproductive endocrinology and infertility specialist is appropriate. In addition to anticoagulation, patients at risk for thrombosis or ovarian hyperstimulation syndrome may benefit from ovarian stimulation protocols that yield lower peak serum estrogen levels, such as those incorporating aromatase inhibitors",
            "We conditionally recommend discontinuation of NSAIDs pre-conception if the patient is having difficulty conceiving (and if disease control would not be compromised), due to the possibility of NSAID-induced unruptured follicle syndrome, a cause of subfertility We strongly recommend against use of NSAIDs in the third trimester because of the risk of premature closure of the ductus arteriosus We conditionally recommend nonselective NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2",
            "serum estrogen levels, such as those incorporating aromatase inhibitors Embryo and oocyte cryopreservation. Embryo and oocyte cryopreservation are good options to preserve fertility in patients whose condition is stable enough for them to undergo ovarian stimulation but who are either not able or not ready to pursue pregnancy at the time of stimulation. A carefully monitored ovarian stimulation/IVF cycle followed by embryo transfer to a surrogate is an option, if available, for patients with"
        ]
    },
    {
        "pregunta": "12. What contraceptive methods are recommended for women with RMD receiving mycophenolate mofetil (MMF)?",
        "respuesta": "Para mujeres con enfermedades reumáticas inflamatorias (RMD) que están recibiendo micofenolato mofetilo (MMF), se **recomienda condicionalmente** utilizar:\n\n- **Un dispositivo intrauterino (DIU) solo**, ya sea de cobre o de progestina,  \n- O bien **dos métodos anticonceptivos concomitantes** para asegurar una protección adecuada.\n\nEsta recomendación se debe a que el MMF puede reducir los niveles séricos de estrógeno y progesterona, lo que disminuye la eficacia de los anticonceptivos orales hormonales. Por ello, la combinación de métodos o el uso del DIU, considerado uno de los métodos anticonceptivos más efectivos, se sugiere para evitar embarazos no deseados en este contexto.\n\nEste consejo proviene del programa Risk Evaluation and Mitigation Strategy (REMS) para micofenolato, que reconoce el riesgo de falla anticonceptiva relacionado con la interacción del MMF con hormonas anticonceptivas.",
        "contexto": [
            "College of Obstetricians and Gynecologists recommends caution regarding DMPA use in women with or at increased risk for osteoporosis We conditionally recommend that women with RMD taking mycophenolate mofetil/mycophenolic acid (MMF) use an IUD alone or 2 other methods of contraception together, because MMF may reduce serum estrogen and progesterone levels (in turn reducing the efficacy of oral contraceptives). The Mycophenolate Risk Evaluation and Mitigation Strategy program suggests use of an",
            "that mycophenolate-containing medications may interfere with hormonal contraceptive efficacy. Since IUDs are the most effective contraceptive options, we strongly recommend the IUD (copper or progestin) for women with RMD who are receiving immunosuppressive therapy, despite hypothetical infection risk. IUD-associated infection risk in RMD patients receiving immunosuppressive therapy has not been specifically studied, but studies in women with HIV show no increase In women with RMD who are at",
            "| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|\n| |Women receiving MMF: Use IUD or 2 other methods together [11]|Conditional|\n| |RMD without SLE or aPL: Use highly effective or effective methods† [1]|Strong|\n| |Highly effective methods preferred to effective methods [1A]|Conditional|\n|SLE|SLE with negative aPL and low/stable disease activity: Use highly effective or effective methods† [2]|Strong|\n| |Highly effective methods preferred to effective methods [2A]|Conditional|",
            "197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal",
            "<ul>\n<li>RMD = rheumatic and musculoskeletal disease; LARC = long-acting reversible contraception; IUD = intrauterine device; DMPA = depot medroxyprogesterone acetate; IM = intramuscular; aPL = antiphospholipid antibody; OP = osteoporosis; SLE = systemic lupus erythematosus; STD = sexually transmitted disease.</li>\n</ul>\n\n<p>† Percent of women who will become pregnant within the first year of typical use.</p>\n\n<p>‡ Methods based on the timing of the menstrual cycle.</p>"
        ]
    },
    {
        "pregunta": "13. What ovarian stimulation protocol adjustments may reduce thrombosis risk in women with RMD undergoing ART?",
        "respuesta": "Los ajustes en el protocolo de estimulación ovárica que pueden reducir el riesgo de trombosis en mujeres con enfermedades reumáticas inflamatorias (RMD) que se someten a técnicas de reproducción asistida (TRA) incluyen el uso de **protocolos de estimulación que generan niveles séricos de estrógenos más bajos**, por ejemplo, aquellos que incorporan **inhibidores de la aromatasa**. \n\nEste enfoque es especialmente relevante en pacientes con riesgo de trombosis o síndrome de hiperestimulación ovárica, ya que los niveles elevados de estrógeno durante la estimulación serán menores, disminuyendo así el riesgo trombótico.\n\nAdemás, se recomienda que el tratamiento anticoagulante se suspenda para la recuperación ovocitaria y se reinicie posteriormente para continuar durante el embarazo, bajo el asesoramiento conjunto con el especialista en endocrinología reproductiva y el reumatólogo. \n\nEn resumen:  \n- Utilizar protocolos con menor producción de estrógeno, como los que incluyen inhibidores de la aromatasa.  \n- Manejar el tratamiento anticoagulante adecuadamente durante la recuperación ovocitaria.  \n- Coordinar el manejo multidisciplinario con especialistas en reproducción y reumatología para minimizar riesgos.",
        "contexto": [
            "197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal",
            "every 12 hours), with this treatment withheld for retrieval and resumed subsequently, to continue throughout pregnancy. Since ovarian stimulation protocols vary, discussion with the reproductive endocrinology and infertility specialist is appropriate. In addition to anticoagulation, patients at risk for thrombosis or ovarian hyperstimulation syndrome may benefit from ovarian stimulation protocols that yield lower peak serum estrogen levels, such as those incorporating aromatase inhibitors",
            "with APS, thrombotic or otherwise, should be cleared medically by their rheumatologist. The rheumatologist should consult with the reproductive endocrinology and infertility specialist regarding adjustments to the ovarian stimulation protocol in order to minimize the risk to the patient. Women with these underlying conditions who undergo fertility therapy should do so only in centers where the appropriate expertise is readily available. We strongly recommend proceeding with ART if needed in",
            "for aPL are at increased risk for thrombosis. Most reports of aPL-positive patients undergoing IVF describe the use of empiric prophylactic anticoagulation due to concern regarding further increased risk of potentially life-threatening thrombosis from elevated estrogen levels during ovarian stimulation. In subfertile patients with RMD who desire pregnancy, have stable/quiescent disease, and have asymptomatic positive aPL, OB APS, or treated thrombotic APS, we conditionally recommend ART with",
            "and outcomes. The ability to become pregnant may itself be an independent concern for some patients, so minimizing risk of gonadal insufficiency is important. RMD patients with subfertility value advice from their rheumatologists about oocyte preservation and in vitro fertilization (IVF). It is difficult to avoid use of medication during pregnancy in patients with RMD. Not all medications are safe for preconception use by men and women or during pregnancy and lactation, but uncontrolled"
        ]
    },
    {
        "pregunta": "14. How should patients with a history of neonatal lupus and positive anti-Ro/SSA antibodies be monitored during pregnancy?",
        "respuesta": "En pacientes embarazadas con antecedentes de lupus eritematoso neonatal (NLE) y positividad para anticuerpos anti-Ro/SSA, se **recomienda condicionalmente** realizar **ecocardiografía fetal semanalmente desde la semana 16–18 hasta la semana 26** del embarazo. \n\nEste monitoreo frecuente busca detectar precozmente posibles signos de compromiso cardíaco fetal, como el bloqueo cardíaco congénito (CHB), que tienen mayor riesgo de recurrencia en mujeres con historia previa de hijo afectado.\n\nEn resumen:\n\n- **Antecedente de hijo con NLE/CHB + anti-Ro/SSA positivo:** ecocardiografía fetal semanal entre semanas 16 y 26 (recomendación condicional).  \n- Este seguimiento es más intensivo que en pacientes sin antecedentes previos, donde se sugieren ecocardiografías seriadas con intervalos menos frecuentes.\n\nEsta vigilancia estrecha permite un diagnóstico oportuno y manejo temprano de complicaciones fetales relacionadas con la presencia de estos anticuerpos.",
        "contexto": [
            "|Positive anti-Ro/SSA with or without anti-La/SSB|Treat with HCQ during pregnancy [69, 70]|Conditional|\n|If no prior history of neonatal lupus: Serial (interval uncertain) fetal echocardiography in weeks 16–26 [67]|Conditional| |\n|If prior history of neonatal lupus: Weekly fetal echocardiography in weeks 16–26 [68]|Conditional| |\n|Medication|Paternal medication| |\n|If planning to father a child: Discuss medication use including CYC|GPS| |",
            "or anti-DNA, C3, or C4 levels may indicate possible SLE flare and/or preeclampsia despite absence of clinical symptoms. Frequency of laboratory monitoring and rheumatology followup may vary with an individual patient's clinical status and medications. Antiphospholipid antibody is a major risk factor for pregnancy loss and other adverse pregnancy outcomes, especially in SLE patients Antiphospholipid antibody Antiphospholipid antibody-positive patients without thrombosis or obstetric",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's",
            "the drug (such as SLE), we conditionally recommend against treating with prophylactic HCQ. As with any unproven treatment, this therapy may be considered in specific circumstances, depending on a patient's values and preferences and after a discussion about risks and benefits. Anti-Ro/SSA and/or anti-La/SSB antibodies in pregnancy. Neonatal lupus erythematosus (NLE) describes several fetal and infant manifestations caused by or associated with maternal anti-Ro/SSA (commonly) and anti-La/SSB",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular"
        ]
    },
    {
        "pregunta": "15. What are the recommendations regarding the use of combined estrogen-progestin contraceptives in patients with systemic lupus erythematosus (SLE) and moderate to high disease activity?",
        "respuesta": "En pacientes con lupus eritematoso sistémico (LES) que presentan **actividad moderada a alta de la enfermedad**, la recomendación es **usar anticonceptivos sólo con progestina o dispositivos intrauterinos (DIU)**. \n\nEl uso de anticonceptivos combinados que contengan estrógeno-progestina, incluyendo el parche transdérmico de estrógeno-progestina, **no está recomendado ni estudiado en pacientes con actividad moderada o alta de LES**. Además, la presencia de anticuerpos antifosfolípidos (aPL), con o sin antecedentes de complicaciones clínicas, es contraindicación para el uso de anticonceptivos combinados debido al riesgo aumentado de trombosis que conlleva el estrógeno.\n\n**En resumen:**\n\n- **LES con actividad moderada a alta:**  \n  - **Se recomienda fuertemente: anticonceptivos sólo con progestina o DIU.**  \n  - **Se recomienda condicionalmente evitar el parche transdérmico combinado.**  \n  - **No usar anticonceptivos combinados** debido a la falta de estudios y riesgo trombótico.\n\nEsta recomendación busca minimizar riesgos de empeoramiento de la enfermedad o eventos trombóticos relacionados con el estrógeno en este grupo de pacientes.",
        "contexto": [
            "use of the transdermal estrogen-progestin patch in patients with SLE. Although not directly studied in SLE patients, the transdermal estrogen-progestin patch results in greater estrogen exposure than do oral or transvaginal methods We strongly recommend progestin-only or IUD contraceptives over combined estrogen-progestin contraception in SLE patients with moderate or severe disease activity, including nephritis, because estrogen-containing contraceptives have not been studied in SLE patients",
            "activity and history of thrombosis In SLE patients with stable or low disease activity who are not positive for aPL, we strongly recommend use of effective contraceptives (i.e., hormonal contraceptives or IUDs) over less effective options or no contraception, and we conditionally recommend the highly effective IUDs or subdermal progestin implant because they have the lowest failure rates. We conditionally recommend against use of the transdermal estrogen-progestin patch in patients with SLE.",
            "estrogen-containing contraceptives have not been studied in SLE patients with moderate or severe disease activity. Antiphospholipid antibody-positive patients. Presence of aPL, with or without history of clinical complications, is a contraindication to use of estrogen-containing contraceptives due the potential further increase in thrombosis risk. We strongly recommend against combined estrogen-progestin contraceptives in women with positive aPL because estrogen increases risk of",
            "| |Avoid transdermal estrogen-progestin patch [2B]|Conditional|\n| |SLE with negative aPL and moderate-to-high disease activity: Use progestin-only contraceptives or IUD [2C]|Strong|\n|Positive aPL|Do not use combined estrogen-progestin contraceptives [3]; use IUD or progestin-only pill [4]|Strong|\n|Assisted reproductive technology|All RMD|GPS|\n| |Stable disease and negative aPL: Proceed with assisted reproductive technology: IVF if pregnancy-compatible medications [24]|Strong|",
            "positive aPL, because risks of emergency contraception are low compared to those of unplanned pregnancy. Levonorgestrel, the over-the-counter option, is widely available and has no medical contraindications to use, including thrombophilia SLE patients. Controlled studies of estrogen-progestin contraceptives in SLE have enrolled only women with stable, low disease activity; they specifically excluded those with high disease activity and history of thrombosis In SLE patients with stable or low"
        ]
    },
    {
        "pregunta": "16. What is the recommended approach to discuss medication use in patients with RMD who are planning pregnancy?",
        "respuesta": "El enfoque recomendado para discutir el uso de medicamentos en pacientes con enfermedades reumáticas inflamatorias (RMD) que están planificando un embarazo incluye:\n\n- **Inicio temprano y diálogo abierto:** Preguntar a la paciente sobre sus deseos reproductivos de manera temprana y periódica, no solo en momentos específicos, para facilitar una comunicación continua y personalizada.\n\n- **Evaluación de factores personales y riesgo:** Reconocer factores personales y riesgos asociados, lo que permite abordar la planificación del embarazo con base en la situación clínica individual.\n\n- **Cambio a medicamentos compatibles con el embarazo:** Antes de la concepción, se debe modificar el tratamiento a fármacos compatibles con el embarazo, buscando estabilidad de la enfermedad.\n\n- **Monitoreo y tratamiento durante el embarazo:** En caso de actividad de la enfermedad durante la gestación, iniciar o ajustar tratamientos compatibles con el embarazo.\n\n- **Co-manejo multidisciplinario:** Involucrar a reumatología junto con ginecología-obstetricia o medicina materno-fetal para optimizar los resultados maternos y fetales.\n\nEste enfoque, basado en evidencia reciente, promueve el control adecuado de la enfermedad con medicamentos compatibles, minimizando riesgos para la madre y el bebé, y mejora los resultados obstétricos en mujeres con RMD que planifican embarazo.",
        "contexto": [
            "recent advances in this area and emphasize the need for early involvement of the rheumatologist in reproductive health discussions involving patients with RMD, for instance, the importance of effective contraception. Almost half of pregnancies in the US are unplanned Asking a patient about desire for pregnancy early and periodically (not only during perceived periods of change) and acknowledging her personal risk factors will ensure open dialog. New information supports a shift from the",
            "use by men and women or during pregnancy and lactation, but uncontrolled systemic inflammatory disease is itself associated with poor pregnancy outcomes Given the primary goal of providing recommendations for care of all adult RMD patients throughout the reproductive lifespan, the scope of this guideline is broad. There has been little attention to aspects of reproductive health care other than pregnancy in patients with RMD, and the American College of Rheumatology (ACR) recognizes the",
            "factors will ensure open dialog. New information supports a shift from the paradigm of discon tinuing all RMD medications except prednisone, since pregnancy-compatible steroid-sparing disease-modifying antirheumatic drugs and biologic agents pose fewer short-and long-term risks to mother and infant. With adequate planning, treatment, and monitoring, most women with RMD can have successful pregnancies. Recent data indicate compatibility of many rheumatology medications both with lactation and",
            "|Pregnancy|All RMD|GPS|\n| |Counseling: Outcomes improved with pregnancy planning, stable disease, compatible medications, and co-management by rheumatology and obstetrics-gynecology/maternal-fetal medicine| |\n| |Pre-pregnancy: Change to pregnancy-compatible medication and observe for stability [42]|Strong|\n| |If active disease during pregnancy: Initiate pregnancy-compatible medication [54]|Strong|",
            "compatibility of many rheumatology medications both with lactation and with paternal use. The rheumatologist's familiarity with drug safety during these periods is important to maintain disease control and minimize mother and infant risk. Fertility and postmenopausal issues are not uncommon in RMD patients. Recommendations regarding ART reflect a growing demand among patients with RMD for fertility therapies. Oocyte freezing is now widely available The strength of evidence on reproductive"
        ]
    },
    {
        "pregunta": "17. How might mycophenolate-containing medications affect the efficacy of hormonal contraceptives in women with RMD?",
        "respuesta": "Los medicamentos que contienen micofenolato pueden **reducir los niveles séricos de estrógeno y progesterona**, lo que **disminuye la eficacia de los anticonceptivos hormonales** en mujeres con enfermedades reumáticas inflamatorias (RMD).  \n\nPor esta razón, se **recomienda condicionalmente** que mujeres en tratamiento con micofenolato utilicen un **dispositivo intrauterino (DIU) solo** (de cobre o progestina) o bien **dos métodos anticonceptivos combinados** para asegurar una protección anticonceptiva adecuada y evitar embarazos no deseados.\n\nEsta recomendación forma parte del programa Risk Evaluation and Mitigation Strategy (REMS) para micofenolato, que reconoce el riesgo de falla anticonceptiva relacionado con la interferencia del micofenolato en los anticonceptivos hormonales.",
        "contexto": [
            "that mycophenolate-containing medications may interfere with hormonal contraceptive efficacy. Since IUDs are the most effective contraceptive options, we strongly recommend the IUD (copper or progestin) for women with RMD who are receiving immunosuppressive therapy, despite hypothetical infection risk. IUD-associated infection risk in RMD patients receiving immunosuppressive therapy has not been specifically studied, but studies in women with HIV show no increase In women with RMD who are at",
            "factors will ensure open dialog. New information supports a shift from the paradigm of discon tinuing all RMD medications except prednisone, since pregnancy-compatible steroid-sparing disease-modifying antirheumatic drugs and biologic agents pose fewer short-and long-term risks to mother and infant. With adequate planning, treatment, and monitoring, most women with RMD can have successful pregnancies. Recent data indicate compatibility of many rheumatology medications both with lactation and",
            "Despite minimal passage of MTX into breast milk, especially with once-weekly dosing, this medication may accumulate in neonatal tissues DISCUSSION Patients' reproductive health concerns are relevant for all practicing rheumatologists. Issues regarding contraception, fertility, pregnancy, lactation, and the offspring's health affect almost every patient across all RMD diagnoses. The importance of this area is highlighted by recent publications that have addressed key elements of reproductive",
            "197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal",
            "| <strong>PICO 16</strong>                                                                           | <strong>MTX: moderate; tofacitinib: low; other medications: indirect evidence only</strong> | PICO 16. Should patients with RMD taking drug Y hold their drug Y for a period of time prior to or after receiving (not live attenuated) vaccines? | 898–927                  |"
        ]
    },
    {
        "pregunta": "18. What contraceptive method is strongly recommended for women with rheumatic and musculoskeletal diseases (RMD) who are receiving immunosuppressive therapy, and why?",
        "respuesta": "Se **recomienda fuertemente el uso de dispositivos intrauterinos (DIU), ya sean de cobre o de progestina**, como método anticonceptivo para mujeres con enfermedades reumáticas y musculoesqueléticas (ERM) que reciben tratamiento inmunosupresor.  \n\n**Razón de esta recomendación:**  \nLos medicamentos que contienen micofenolato, comúnmente usados en el tratamiento inmunosupresor, pueden reducir los niveles séricos de estrógeno y progesterona, lo que **disminuye la eficacia de los anticonceptivos hormonales orales**. El DIU es uno de los métodos anticonceptivos más efectivos y su uso se prefiere a pesar de un riesgo teórico de infección, el cual no ha demostrado aumentar en pacientes con ERM bajo tratamiento inmunosupresor.  \n\nPor lo tanto, para asegurar una protección anticonceptiva adecuada y evitar embarazos no deseados en este contexto, el DIU es la opción más recomendada.",
        "contexto": [
            "197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal",
            "that mycophenolate-containing medications may interfere with hormonal contraceptive efficacy. Since IUDs are the most effective contraceptive options, we strongly recommend the IUD (copper or progestin) for women with RMD who are receiving immunosuppressive therapy, despite hypothetical infection risk. IUD-associated infection risk in RMD patients receiving immunosuppressive therapy has not been specifically studied, but studies in women with HIV show no increase In women with RMD who are at",
            "<p>‡ Methods based on the timing of the menstrual cycle.</p>\n\n<h1>Table 2. Recommendations regarding medication use for men with rheumatic and musculoskeletal disease who are planning to father a child</h1>",
            "<ul>\n<li>RMD = rheumatic and musculoskeletal disease; LARC = long-acting reversible contraception; IUD = intrauterine device; DMPA = depot medroxyprogesterone acetate; IM = intramuscular; aPL = antiphospholipid antibody; OP = osteoporosis; SLE = systemic lupus erythematosus; STD = sexually transmitted disease.</li>\n</ul>\n\n<p>† Percent of women who will become pregnant within the first year of typical use.</p>\n\n<p>‡ Methods based on the timing of the menstrual cycle.</p>",
            "use of effective contraceptives (i.e., hormonal contraceptives or IUDs) over less effective options or no contraception; among effective methods, we conditionally recommend the highly effective IUDs or subdermal progestin implant (long-acting reversible contraceptives) because they have the lowest failure rates. We strongly recommend discussing use of emergency contraception with all patients, including those with SLE or positive aPL, because risks of emergency contraception are low compared to"
        ]
    },
    {
        "pregunta": "19. What anticoagulation regimen is typically used prophylactically during ovarian stimulation in asymptomatic aPL-positive patients?",
        "respuesta": "En pacientes asintomáticas con positividad para anticuerpos antifosfolípidos (aPL) que se someten a estimulación ovárica durante técnicas de reproducción asistida (TRA), no existe un esquema habitual estándar de anticoagulación profiláctica establecido debido a la falta de estudios comparativos o evidencia sólida en este grupo específico.\n\nSin embargo, dado que la estimulación ovárica conlleva un aumento del riesgo trombótico por elevación de estrógenos, y que los pacientes aPL positivos tienen riesgo incrementado de trombosis, **la anticoagulación profiláctica con heparina no fraccionada o heparina de bajo peso molecular (HBPM) es frecuentemente usada de forma empírica** durante el período de estimulación ovárica y continuidad hasta que los niveles de estrógeno regresan a niveles fisiológicos, especialmente si no ocurre embarazo.\n\nLa decisión sobre la duración óptima y el inicio de esta profilaxis debe realizarse de forma individualizada en consulta multidisciplinaria con especialistas en endocrinología reproductiva e inmunología/reumatología.\n\nEn resumen:  \n- No hay un esquema formal establecido ni datos concluyentes para anticoagular en forma profiláctica a pacientes asintomáticas aPL positivas en estimulación ovárica.  \n- Se usa frecuentemente, de manera preventiva, HBPM o heparina no fraccionada desde el inicio de la estimulación y hasta 6-12 semanas post-procedimiento o hasta normalización de estrógenos si no hay embarazo.  \n- La decisión debe estar basada en valoración de riesgo individual y coordinación multidisciplinaria.",
        "contexto": [
            "and resumed following retrieval. Optimal duration of prophylactic LMWH for asymptomatic aPL-positive patients undergoing ovarian stimulation has not been studied; this is a decision best made in consultation with the reproductive endocrinology and infertility specialist. The treatment is often continued until estrogen levels return to near-physiologic levels if no pregnancy occurs. Patients with OB APS will continue therapy throughout pregnancy. Aspirin is not commonly used prior to oocyte",
            "for aPL are at increased risk for thrombosis. Most reports of aPL-positive patients undergoing IVF describe the use of empiric prophylactic anticoagulation due to concern regarding further increased risk of potentially life-threatening thrombosis from elevated estrogen levels during ovarian stimulation. In subfertile patients with RMD who desire pregnancy, have stable/quiescent disease, and have asymptomatic positive aPL, OB APS, or treated thrombotic APS, we conditionally recommend ART with",
            "antibody-positive patients without thrombosis or obstetric complications. Asymptomatic aPL-positive patients (those without pregnancy complications or history of thrombosis) are not generally treated with prophylactic therapy to prevent pregnancy loss. However, presence of aPL regardless of clinical history is considered a risk factor for development of preeclampsia. In pregnant women with positive aPL who do not meet criteria for obstetric or thrombotic APS, we conditionally recommend treating",
            "6-12 weeks post partum In pregnant women with thrombotic APS, we strongly recommend treating with low-dose aspirin and therapeuticdose heparin (usually LMWH) throughout pregnancy and post partum. We conditionally recommend against using the combination of prophylactic-dose heparin and low-dose aspirin therapy for patients with positive aPL who do not meet criteria for OB APS. We appreciate and stress, however, that benefit in individual high-risk circumstances, such as triple-positive aPL or",
            "of unfractionated heparin or low molecular weight heparin (LMWH). We strongly recommend prophylactic anticoagulation with heparin or LMWH in women with OB APS, and we strongly recommend therapeutic anticoagulation in women with thrombotic APS, during ART procedures. The strength of these recommendations rests on the severity of the risk of organ-or life-threatening thrombosis during ovarian stimulation. An added risk for thrombosis is ovarian hyperstimulation syndrome, an important, uncommon"
        ]
    },
    {
        "pregunta": "20. Why is repeated testing for anti-Ro/SSA and anti-La/SSB antibodies during pregnancy generally not recommended?",
        "respuesta": "Generalmente, no se recomienda la realización repetida de pruebas para anticuerpos anti-Ro/SSA y anti-La/SSB durante el embarazo porque estos anticuerpos presentan una persistencia relativa y sus títulos no cambian durante la gestación. Por ello, se considera suficiente realizar un único test antes o temprano en el embarazo para evaluar el riesgo fetal asociado. Esta recomendación está basada en evidencia que indica que la repetición de estas pruebas no aporta información adicional relevante para el manejo clínico durante la gestación.",
        "contexto": [
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular",
            "steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's",
            "by or associated with maternal anti-Ro/SSA (commonly) and anti-La/SSB autoantibodies. While isolated anti-La/SSB rarely imposes risk, when combined with anti-Ro/SSA, La/SSB antibodies may increase fetal risk Complete (third-degree) heart block (CHB) occurs in ~2% of pregnancies of women with anti-Ro/SSA and/or anti-La/SSB antibodies who have not had a prior infant with NLE, and in 13-18% of pregnancies of women with a prior infant who had either cutaneous or cardiac NLE http://onlin elibr ary.",
            "| |If SLE or SLE-like disease, SS, SSc, or RA: Test once (early) for anti-Ro/SSA and anti-La/SSB [60, 62]|Strong|\n| |If SSc and renal crisis during pregnancy: Treat with ACE inhibitor or ARB for life-threatening disease [55]|Strong|\n|SLE|SLE or SLE-like disease: Test once (early) for aPL (aCL, anti-β₂GPI, LAC) [59, 61]|Strong|\n|Continue HCQ during pregnancy [57]|Strong| |\n|If not taking HCQ, start HCQ during pregnancy if no contraindications [58]|Conditional| |",
            "or anti-DNA, C3, or C4 levels may indicate possible SLE flare and/or preeclampsia despite absence of clinical symptoms. Frequency of laboratory monitoring and rheumatology followup may vary with an individual patient's clinical status and medications. Antiphospholipid antibody is a major risk factor for pregnancy loss and other adverse pregnancy outcomes, especially in SLE patients Antiphospholipid antibody Antiphospholipid antibody-positive patients without thrombosis or obstetric"
        ]
    }
]